We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

21 hedge funds and large institutions have $9.64M invested in Evoke Pharma in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

22% more capital invested

Capital invested by funds: $7.92M → $9.64M (+$1.72M)

5% more funds holding

Funds holding: 20 → 21 (+1)

0% more ownership

Funds ownership: 0.13% → 0.13% (+0%)

Holders
21
Holders Change
+1
Holders Change %
+5%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFM
Boothbay Fund Management
New York
+$112K
2
JP Morgan Chase
JP Morgan Chase
New York
+$103K
3
Morgan Stanley
Morgan Stanley
New York
+$31.1K
4
VF
Virtu Financial
New York
+$30.3K
5
UBS Group
UBS Group
Switzerland
+$18K

Top Sellers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
-$62K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$32K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$24.7K
4
TSS
Two Sigma Securities
New York
-$798
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
1
Sphera Funds Management
Israel
$4.21M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.6M – – –
SOMRS
3
State of Michigan Retirement System
Michigan
$1.19M – – –
KCM
4
Knoll Capital Management
Florida
$825K – – –
6CM
5
683 Capital Management
New York
$341K – – –
Creative Planning
6
Creative Planning
Kansas
$298K – – –
BlackRock
7
BlackRock
New York
$236K +$7.98K +20 +4%
BFM
8
Boothbay Fund Management
New York
$120K +$112K +280 New
JP Morgan Chase
9
JP Morgan Chase
New York
$111K +$103K +259 New
California Public Employees Retirement System
10
California Public Employees Retirement System
California
$109K – – –
Northern Trust
11
Northern Trust
Illinois
$101K – – –
Commonwealth Equity Services
12
Commonwealth Equity Services
Massachusetts
$96K -$24.7K -62 -22%
PNC Financial Services Group
13
PNC Financial Services Group
Pennsylvania
$82K – – –
VF
14
Virtu Financial
New York
$80K +$30.3K +76 +70%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$68K – – –
TSS
16
Two Sigma Securities
New York
$55K -$798 -2 -2%
UCFA
17
United Capital Financial Advisors
Texas
$46K – – –
Morgan Stanley
18
Morgan Stanley
New York
$46K +$31.1K +78 +252%
UBS Group
19
UBS Group
Switzerland
$21K +$18K +45 +1,500%
Bank of America
20
Bank of America
North Carolina
$8K +$7.98K +20 New
Citigroup
21
Citigroup
New York
$1K – – –
Bank of New York Mellon
22
Bank of New York Mellon
New York
– -$62K -173 Closed
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
– -$32K -89 Closed

EVOK Hedge Fund Activity: Q3 2018 in Review

21 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2018, worth a combined $9.64M — up 22% from $7.92M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new EVOK positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $112K. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $62K sold.

  • 21 institutional investors held Evoke Pharma (EVOK) as of Q3 2018, up from 20 in Q2 2018.
  • Funds reported $9.64M of Evoke Pharma stock for Q3 2018, up 22% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q3 2018 and 2 closed out, a net change of +1 holder.
  • The largest Evoke Pharma buyer in Q3 2018 was Boothbay Fund Management, an estimated $112K added.
  • The largest Evoke Pharma seller in Q3 2018 was Bank of New York Mellon, an estimated $62K sold.

Based on aggregated 13F filings for Q3 2018.